Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Parkinson's disease (PD) is the second most common progressive neurodegenerative
disorder mainly in middle‐elderly population, which represents diverse nonmotor symptoms …

Besides motor symptoms, many individuals with Parkinson's disease develop cognitive
impairment perhaps due to coexisting α-synuclein and Alzheimer's disease pathologies and …

The glymphatic system is a unique pathway that utilises end-feet Aquaporin 4 (AQP4)
channels within perivascular astrocytes, which is believed to cause cerebrospinal fluid …

With varying clinical symptoms, most neurodegenerative diseases are associated with
abnormal loss of neurons. They share the same common pathogenic mechanisms involving …

ABSTRACT PD, PD with dementia, and dementia with Lewy bodies are clinical syndromes
characterized by the neuropathological accumulation of alpha‐synuclein in the CNS that …

The aggregation of amyloid-beta peptide and tau protein dysregulation are implicated to
play key roles in Alzheimer's disease pathogenesis and are considered the main …

Although not fully understood, sleep is accepted as a vital and organized sequence of
events that follows a regular cyclic program each night to ensure the human body can …

Cognitive impairment is one of the most salient non-motor symptoms of Parkinson disease
(PD) that poses a significant burden on the patients and carers as well as being a risk factor …

Cognitive impairment (CI) is a characteristic non-motor feature of Parkinson disease (PD)
that poses a severe burden on the patients and caregivers, yet relatively little is known about …